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988that includes “shrink-wrapping” deformation, noise
averaging, and outer/inner surface creation using
viewing windows. Although these steps are essential
to model extraction, each step steers us further away
from source data. At what point does the anatomic
model become an aesthetic sculpture?
This is illustrated by our own 3DP experience. We
derived a 3D model of an aortic root with anomalous
coronaries from a cardiac computed tomography
angiography image using a Siemens Sensation
64-slice scanner (Siemens Medical Solutions Inc.,
Malvern, Pennsylvania) and printed it on a Stratasys
Dimension Elite station (Stratasys Ltd., Minneapolis,
Minnesota) using acrylonitrile butadiene styrene
plastic (Figure 1). Our model was not manually edited.
Figure 1A shows a fracture due to fragility at a
previous stent site (arrow). Since the contrast-
endovascular interface is nonuniform, variability in
extraction results in “holes” in the model
(Figure 1B). Image processing can “ﬁx” these holes
and offset fragility; however, this diverts us away
from true anatomy.
Lastly, the elasticity of print materials must be
validated against that of cardiac tissues. Without
this, physical interaction with models is unreliable.
The material properties of the IVC model of O’Neill
et al. (1) are unclear. In this case, printing with stiff
plastic, rubber, or metal could potentially alter
device selection. Recently, a mitral valve was
printed with pliable materials (5). As elucidatedof an Aortic Root With Anomalous Right Coronary Artery Origin
emonstrated by a fracture at the site of a previous stent (arrow). (B)
ons (“holes”) visible in the 3D model resulting from model extraction
uniform contrast-endovascular interface. 3D ¼ 3-dimensional.in this work, using materials mimicking tissue
properties could lead to applications in ex vivo
device testing and training. In our own aortic root
model (Figure 1B), for example, printing with a
pliable material could enable preliminary test
interactions with transcatheter valves.
In conclusion, we share the enthusiasm for the
potential of 3DP in SHD. However, multiple technical
aspects must be ﬁrst standardized and validated
before meaningful clinical strides can be made with
3DP in the clinical domain.Moses Mathur, MD, MSc*
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Heart Disease: All That Glitters Is Not GoldWe thank Dr. Mathur and colleagues for their interest
in our experience with computer-aided design and
3D printing (CAD3DP) in structural heart disease
periprocedural planning (1). We agree that in the
eventual technological investment in personalized
heart valves, there will need to be standardization
of 3D printing for health care delivery. The focus,
however, should not be on the 3D print itself, but
the integration of advanced multidetector slice
computed tomography (CT) image reconstruction
with CAD3DP for successful periprocedural planning.
TABLE 1 Transcatheter CAVI CT Scanning Protocol
Scan type: gated CTA abdomen
Field of view
Start scan acquisition: at the level of the carina
Complete scan acquisition: at the bottom of rib cage
Algorithm: standard
Scan helical thickness: 1.25 mm
*Pitch:gantry rotation speed, s
0.16:0.36
0.18:0.36
0.20:0.36
0.22:0.36
0.24:0.36
BMI
100 kV if BMI <30 kg/m2
120 kV if BMI >30 kg/m2
ECG modulated mA
Minimum of 200 to maximum of 600
Cardiac RR 40–80
Adaptive statistical iterative reconstruction: 30%
Recon 2 (periprocedural planning analysis of RA-IVC junction):
0.625 mm (0%-45% of cardiac cycle as this coincides with
maximal right atrial ﬁlling in systole)
Recon 3 (for additional radiological ﬁndings): 2.5 mm (30%)
Recon 4 (CAVI valve cine loop series): 1.25 mm (0%-95% by 10%
increments for cine loop of dynamic ﬂow and evaluation for
perivalvular leak)
Prep delay: Smartprep at mid-descending thoracic aorta at level of
diaphragm
Injection rate: 5 ml/s
Injection volume: 100 ml
Autotransfer: PACS
Enter GATED CAVI in exam description
Set maximal mA at phases 35–80 and r peak center to 75
INJECTOR PROTOCOL
5 ml/s 100 ml contrast
3 ml/s 30 ml saline solution
*Pitch: speed should be adjusted according to the heart rate gating algorithm
provided by different vendors as recommended for routine cardiac gating
acquisition protocols.
BMI ¼ body mass index; CAVI ¼ caval valve implantation; CT ¼ computed to-
mography; CTA ¼ computed tomography angiography; ECG ¼ electrocardiogram;
PACS ¼ radiology picture archiving communications system; RR ¼ electrocardio-
gram R-R interval; RA-IVC ¼ right atrial-inferior vena cava.
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989First, CAD3DP application is only as usable as the
quality of the CT raw source DICOM data that it is being
applied from,asdemonstratedby theartifacton themodel
of Mathur and colleagues. For this to be avoided, there
needs to be signiﬁcant investment in education for scan-
ning techniqueandscan implementationat the levelof the
CT technologists. For structural heart interventions, we
tailor our CT scans to the speciﬁc valve or area of interest
(Table 1). We use a contrast-enhanced, retrospectively
electrocardiogram-gated CT angiography acquisition
on a General Electric Discovery CT750 64-slice scanner(General Electric, Waukesha, Wisconsin). Additionally,
targeted cardiac phases are identiﬁed for reconstruction,
as this affects the size, geometry, and functionality of the
area of interest. Our models are printed on the Objet30
(Stratasys Ltd., Minneapolis, Minnesota) using Rigid
Opaque photopolymers (Stratasys Ltd.).
Second, there is no current U.S. Food and Drug
Administration–approved medical 3D printer for use.
The absence of elastic printed materials that mimic
human tissue should not preclude the advancement
and adjunctive clinical application of this technology
to current transcatheter procedures for physical peri-
procedural information gathering and planning.
Technology for the future bioprosthetic 3D printed
heart valve does not yet exist, but periprocedural
clinical application of CAD3DP in structural heart
interventions is the beginning to developing the plat-
form to reach that ultimate goal.
We therefore caution comparing medical 3D
printing in its infancy with “aesthetic art.” There is a
vast difference in the amount of procedural planning
awareness generated between the ability to view an
image magniﬁed on a computer monitor compared
with handling a to-scale reproduction of a patient’s
anatomy with tolerances that do not modify or
deform. Moving forward, we will continue to develop
and advance CT CAD3DP imaging innovation to
enhance the care of our patients requiring high-risk
advanced structural heart interventional therapy.Brian O’Neill, MD
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